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Background: Celiac disease is a life-long autoimmune condition, affecting genetically susceptible individuals that
may present with thromboembolic phenomena. This thrombophilia represents a puzzle with multiple constituents:
hyperhomocysteinemia, B12 and\or folate deficiency, methylenetetrahydrofolate reductase mutations, and protein C
and S deficiency due to vitamin K deficiency. However, the well known thrombogenic factors,
antiphosphatidylserine/prothrombin and antiprothrombin have never been explored in celiac disease.
Methods: The serum autoantibody levels were determined in 248 individuals, classified into three groups. Group 1
comprised 70 children with definitive celiac disease (age: 7.04 ±4.3 years, male to female ratio 1.06) and group 2
comprised 88 normal children (age: 6.7 ±4.17 years, male to female ratio 0.87), representing controls. The pediatric
populations were compared to group 3, which included 90 adults who were family members (parents) of group 1
(age: 34.6 ±11.35 years, male to female ratio 1.2). Antibodies were checked by enzyme-linked immunosorbent assay.
Results: Mean optical density levels of serum antiphosphatidylserine/prothrombin immunoglobulin G antibodies
were 32.4 ±19.4, 3.6 ±2.5 and 16.1 ±15.8 absorbance units in groups 1, 2 and 3 respectively (P <0.0001), with 45.7%,
0% and 7.8% of groups 1, 2 and 3 respectively positive for the antibody (P <0.01). Mean optical density levels of
serum antiphosphatidylserine/prothrombin immunoglobulin M antibodies were 14.2 ±8.7, 6.7 ±6.4 and 12.4 ±15.5
absorbance units in groups 1, 2 and 3 respectively (P <0.0001), with 7.1%, 3.4% and 9.9% of groups 1, 2 and 3
positive for the antibody. Mean optical density levels of serum antiprothrombin and antiphospholipid
immunoglobulin G antibodies were higher in groups 1 and 3 compared with 2 (P <0.005) and in groups 1 and 2
compared with 3 (P <0.01), respectively. Groups 1, 2 and 3 were positive for antiphospholipid immunoglobulin G
antibodies (groups 1 and 2 compared with 3) . Celiac disease sera harbor a higher antiprothrombin
immunoglobulin G level compared with controls.
Conclusions: It is suggested that the intestinal injury, endothelial dysfunction, platelet abnormality and enhanced
apoptosis recently described in celiac disease are at the origin of the increased exposure of phospholipids or new
epitopes representing autoantigens. Those autoantibodies might play a pathogenic role in the thrombophilia
associated with celiac disease and represent markers for potential anticoagulant preventive therapy.
Keywords: Antiphosphatidylserine/prothrombin, Autoantibodies, Celiac disease, Hypercoagulability, Phospholipid,
Prothrombin* Correspondence: lerner_aaron@clalit.org.il
†Equal contributors
1Pediatric Gastroenterology and Nutrition Unit, Carmel Medical Center, B.
Rappaport School of Medicine, Technion-Israel institute of Technology,
Michal St. No 7, Haifa 34362, Israel
Full list of author information is available at the end of the article
© 2013 Lerner et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Lerner et al. BMC Medicine 2013, 11:89 Page 2 of 7
http://www.biomedcentral.com/1741-7015/11/89Background
Celiac disease (CD) is the most common autoimmune
food intolerance in the world. It is a life-long autoimmune
condition [1] mainly of the gastrointestinal tract, affecting
the small intestine of genetically susceptible individuals.
Environmental factors are crucial for disease induction.
Gluten, which is the storage protein of wheat and its
alcohol-soluble gliadins are the offending inducers of the
disease together with structurally related molecules found
in barley, rye and oat. Tissue transglutaminase (tTG) is
the autoantigen against which the abnormal immune
response is directed [2] and two main autoantibodies,
antiendomysium and anti-tTG, are currently the most
useful serological markers to screen for the disease [3,4].
The sequential chain of events operating in the disease
was recently unraveled, and gives hope for future
therapeutic strategies [5]. Furthermore, the epidemiology,
prevalence and clinical presentation of CD are changing
constantly and, with time, new clinical presentations are
depicted that increase the clinical variability of CD [6].
It has been shown that the classical intestinal clinical
picture of malnutrition, chronic diarrhea and nutritional
deficiencies are disappearing and extraintestinal presen-
tations are emerging. Skin, endocrine, skeletal, hepatic,
hematological, gynecological, fertility, dental and behav-
ioral abnormalities are often described [7-9]. Nowadays,
we are witnessing an epidemiological shift in the disease
phenotype toward a more advanced age, and increased
prevalence of latent, hyposymptomatic or asymptomatic
presentations [6].
A newly explored area of CD is hypercoagulability and
the resulting thromboembolic phenomena. There is an
increase risk of stroke in adults and children with CD
[10-15]. Thrombophilia, pregnancy loss, deep vein
thrombosis, small bowel infarction, atrial fibrillation,
Budd-Chiari syndrome, portal and splenic vein throm-
bosis, and cardiovascular disease have been described
[16-21]. Even the onset of the disease may be due to a
thrombotic event [11,17,21]. Hyperhomocysteinemia
with related vitamin deficiency in untreated CD, the fre-
quency of methylenetetrahydrofolate reductase variants
and the high homology between factor XIII and tTG add
to the hypercoagulable status in patients [21-26].
In fact, there is an increased incidence of autoimmune
diseases in CD [1,7,27,28]. Two examples associated with
thrombophilia are systemic lupus erythematosus (SLE)
and antiphospholipid (aPL) syndrome [29,30]. Three
autoantibodies associated with the two entities are
antiphosphatidylserine/prothrombin (aPS/PT), aPL and
antiprothrombin (aPT). aPS/PT and aPL autoantibodies
confer increased risk for thromboembolic events and poor
outcome in those diseases [31-39]. The correlation be-
tween aPS/PT antibodies and clinical manifestations of
aPL syndrome and the importance of aPS/PT as a markerfor this syndrome are well established. The relationship
between aPS/PT antibodies and hypercoagulability state is
further strengthened by their increased incidence in cere-
bral infarction [40]. aPT autoantibodies are prevalent in
SLE and aPL syndrome and are associated with throm-
bosis and pregnancy morbidity [41-44].
Despite the coexistence of CD and thromboembolic
events, the aPS/PT and aPT status has never been investi-
gated and aPL activity has scarcely been investigated in CD.
On the above backgrounds of aPS/PT, aPT and aPL anti-
bodies and thrombophilia, hypercoagulability in CD, and
increased incidence of SLE and aPL in CD, the presence of
aPS/PT, compared with aPL, aPT and anticardiolipin anti-
bodies, were explored in children with CD and their par-
ents, compared with pediatric controls. Increased incidence
of aPS/PT IgG in the celiac group and intermediate inci-
dence in their parents, compared with none in the control
group, was detected. Additionally, higher rates of activities
of aPS/PT IgM and prothrombin IgG autoantibodies in the
celiac patients compared with the other two groups were
detected. It seems that the presently studied thrombophilic
autoantibodies are operative in CD, extending the
hypercoagulability network in this disease.
Methods
Study populations
Serum aPS/PT, aPT and aPL autoantibodies levels were
determined in 248 individuals, divided into three groups.
Group 1 comprised 70 Israeli children with definitive CD
(age 7.04 ±4.3 years, male to female ratio 1.06). Group 2
was represented by 88 normal children (age 6.7 ±4.17
years, male to female ratio 0.87) as controls. The pediatric
populations were compared with group 3, which included
90 family members (parents) of group 1 (age 34.6 ±11.35
years, male to female ratio 1.2).
The following information was collected on the three
groups: diet - gluten-containing or gluten-free; symptoms -
abdominal pain, short stature, vomiting, diarrhea, anemia,
failure to thrive and IgA deficiency; familial diseases - CD,
diabetes mellitus type 1 or 2, familial Mediterranean fever,
inflammatory bowel disease, thyroid disease; laboratory pa-
rameters - complete blood count, biochemical profile, IgA
levels, CD serology (see ELISA assays below).
CD was diagnosed according to the revised criteria of
the European Society for Pediatric Gastroenterology and
Nutrition, based on specific serology and duodenal biop-
sies [45]. All the participants were on a gluten-containing
diet and were checked for celiac serology.
ELISA assays
Celiac serology
Three ELISA assays are included in our celiac screening
algorithm, as recently described [4,46]. Briefly, The
AESKU celiCheck (Aesku.Kipp Institute, Wendelsheim,
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those antibodies against the new epitopes created in the
transformed complex of gliadin-tTG. In this study, we
evaluated The AESKU CeliCheck Neo-epitope assay on
the TRITURUS analyzer (GRIFOLS SA, Barcelona
Spain). All the participants were additionally screened
for tTG IgA assay on the Liaison (DiaSorin, Saluggia,
Italy) and the ORGENTEC tTG IgA plus IgG assay on
the ETI-MAX 3000 analyzer (DiaSorin). National exter-
nal quality assessment site is routinely used as the exter-
nal quality control program.
Anticardiolipin, phospholipid, prothrombin and aPS/PT
essays
Sera were tested for anticardiolipin, phospholipid, pro-
thrombin and aPS/PT antibodies using solid phase enzyme
immunoassay (AESKULISA, AESKU diagnostics ( Aesku.
Kipp Institute, Wendelsheim, Germany) , according to the
manufacturer’s protocol.
Briefly, serum samples were diluted 1:100 and incubated
in microplates coated with the specific antigen. Binding
was detected by antihuman immunoglobulins peroxidase
(conjugate) and 3,3',5,5'-Tetramethylbenzidine-substrate.
The sera was identified as positive for the antibodies
according to the manufacture's equations for cut-off value
determination or using other cut-offs as specified below:
Cardiolipin check - The immunoassay employed highly
purified cardiolipin plus native human beta2-cardiolipin
1 for the combined quantitative and qualitative detection
of IgA, IgM and IgG antibodies against cardiolipin in the
sera. Positive cut-off was >24 U/ml.
Phospholipid IgG and IgM - As for the cardiolipin
check except for the use of antihuman IgG and IgM
peroxidise. Positive cut-off for both antibodies
was >18 U/ml.
Prothrombin IgG - The immunoassay employed
highly purified prothrombin (factor ІІ) for the
combined quantitative and qualitative detection of IgG
antibodies against prothrombin in the sera. Antihuman
IgG peroxidase conjugate was employed. Positive cut-
off was >18 U/ml.
Phosphatidylserine/prothrombin IgA, IgG and IgM -
The immunoassay employed highly purified
phosphatidylserine plus native human prothrombin for
the combined quantitative and qualitative detection of
IgA, IgM and IgG antibodies against PS/PT in the sera.
Antihuman IgA, IgG and IgM peroxidase conjugates
were used. Positive cut-off for PS/PT -IgA was >28 U/ml.
The manufacturers cut-off is 18 U/ml. Based on multiple
determinations on 92 healthy Israeli participants, a
higher cut-off of the mean plus two SD was used. The
receiver operating characteristic curve data were: area
under the curve 0.855; standard error 0.0315; 95%confidence interval 0.791, 0.905; Z statistic 11.258; and
P <0.0001.
Endoscopy and intestinal histology
All patients in group 1 underwent esophagogastro-
duodenoscopy using a GIF-xp 20 endoscope (Pentax,
Tokyo, Japan). At least five biopsies were obtained: four
from the second part of the duodenum for the diagnosis or
exclusion of CD and one from the antrum.
The biopsies were immediately fixed in buffered forma-
lin and embedded on edge in paraffin. Sections were
stained with hematoxylin-eosin and Giemsa, analyzed by
the pathologist and graded according to Marsh criteria, as
previously described [3]. On the day of endoscopy, 5 ml of
peripheral blood was withdrawn, centrifuged at 5000 c/s
for 10 minutes, and the serum frozen in −80° Celsius until
assayed for serology.
The ethical committee of Carmel Medical Center ap-
proved the study and written informed consent was
obtained from the parents or guardians of the children.
Statistical analysis
Data analysis was performed using the PASW 18 statis-
tical package (PASW, Chicago, IL, USA). A comparison
of the levels of anticardiolipin, phospholipid, prothrom-
bin and aPS/PT autoantibodies between the three study
groups was performed by a Kruskal-Wallis test. For mul-
tiple comparisons between any two study groups, a
Mann Whitney test was used. For examining the associ-
ation between the positive cut-offs for all antibodies with
the study groups, a Chi square test or exact test for
small sample was used. All P values were two-sided, and
statistical significance was defined as P <0.05.
Results
No epidemiological statistical difference between the
pediatric groups (groups 1 and 2) was detected. None of
the participants were IgA deficient and all were screened
also by IgG-tTG antibodies. None of the parents (group
3) at the time of the study had positive serology for CD,
despite consuming gluten. No correlation was found be-
tween parents and children concerning the results.
Table 1 shows the mean ±SD and median of the differ-
ent autoantibodies in group 1 (pediatric CD), group 2
(pediatric control) and the parents of group 1. Table 2
shows the mean of percentage positivity of the optical
density of the autoantibodies in group 1 (pediatric CD)
and group 3 (parents) compared with the healthy controls,
group 2.
Discussion
The main result of the present study is the increased in-
cidence of aPS/PT IgG in the celiac group and inter-
mediate incidence in their parents, compared with none
Table 1 Mean and median of autoantibodies' activity in celiac children, their parents compared to pediatric controls














ND ND ** ND 10.7 ±13.6 (8.2) 7.9 ±9.5 (5.6) aPS/PT IgA
** ** ** 3.6 ±2.5 (3.3) 16.1 ±15.9 (12.3) 32.4 ±19.5 (27.7) aPS/PT IgG
** ** ** 6.7 ±6.4 (4.9) 12.4 ±15.5 (8.6) 14.2 ±8.7 (12.9) aPS/PT IgM
* ** * 11.9 ±15.8 (6.0) 12.4 ±18.2 (7.9) 15.2 ±19.5 (10.6) Prothrombin IgG
** ** ** 9.4 ±7.0 (8.6) 8.0 ±10.4 (5.8) 10.4 ±6.0 (9.1) Phospholipid IgG
ND ND * ND 3.9 ±6.9 (1.7) 3.3 ±2.8 (2.5) Phospholipid
IgM
NS NS ** 5.5 ±3.4 (4.9) 2.9 ±2.1 (2.2) 4.5 ±2.6 (4.4) Cardiolipin check
*P <0.001; ** P <0.0001; aPL: antiphospholipid; aPS/PT: antiphosphatidylserine/prothrombin; aPT: antiprothrombin; Ig: immunoglobulin; ND: not done NS:
non-significant; SD: standard deviation.
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rates of aPS/PT IgM and prothrombin IgG autoantibodies
in the celiac patients compared with the other two groups.
Of note is the constant, parallel, gradual decrease of the
levels of aPS/PT IgG and IgM across the continuum of the
three groups, from celiac children, to their parents, to
pediatric controls. The fact that none of the parents had
positive celiac serology points to a potential genetic influ-
ence on the presence of aPS/PT autoantibodies. In fact, be-
ing an autoimmune disease with a well-established genetic
susceptibility and increased familial predisposition, the in-
creased presence of autoantibodies and autoimmune dis-
eases in first-degree relatives of CD patients is well known
[47-49] and aPS/PT should be added to the list. Addition-
ally, aPS/PT should be added to the increasing list of auto-
antibodies associated with CD-affected patients [27,28].
Despite the fact that many of the autoantibodies might
present an epiphenomenon, it is suggested that mainly
aPS/PT, but also antithrombin and aPL autoantibodies,
are pathogenic and play an active role in CD pathogenesis
and complications. The presence of aPS/PT is directly re-
lated to thromboembolic events in aPL syndrome, SLE
and cerebral infarction [31-40]. The thrombogenic proper-
ties of aPS/PT correlate with increased thrombin gener-







<0.9 ND. 3.3 4.3
<0.0001 0***,** ***7.8, ** 45.7***
0.23> 3.4 9.9 7.1
0.5> 14.9 11 17.1
0.07> *12.5 *3.3 11.4
1> ND. 2.2 1.4
1> 0 1.1 0
*P <0.05,**P <0.01,***P <0.0001; aPS/PT: antiphosphatidylserine/prothrombin; aPT: aof the pathophysiology of thrombophilia in these patients
[36]. Those autoantibodies are strong risk factors for ven-
ous thromboembolism in patients with SLE because they
induce activated protein C resistance [37]. The other two
IgG autoantibodies, namely antithrombin and aPL, are
also associated with thrombotic events in aPL syndrome
and SLE [32,33,50,51], and are risk factors for myocardial
infarction in middle-aged men [52,53].
The pathophysiology of the thromboembolic phenom-
ena associated with CD [10-26] represents a puzzle with
multiple constituents: hyperhomocysteinemia; B12 and
\or folate deficiency; methylenetetrahydrofolate reduc-
tase mutations; the high homology between blood co-
agulation factor XIII and tTG; and protein C and S
deficiency due to vitamin K deficiency [21-26,54]. The
present study unravels a series of autoantibodies, aPL,
aPT and mainly aPS/PT, that form part of this puzzle
and are suggested to play a pathogenic role in the
thrombogenicity of CD.
Phosphatidylserine is a regular constituent of the inner
leaflet of the cell membrane, which is only exposed on
the outside of the cell membrane during apoptosis or
because of damaged endothelial cells [55]. It is known
that prothrombin and aPL antibodies bind specifically to
the surface of apoptotic cells [56,57]. Recently, Iekoren and their parents compared with pediatric controls
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thrombin bound to phosphatidylserine on platelets and
endothelial cells and, directly or via Fc-gamma receptors,
activates a variety of procoagulant agents. However, the
complementary aspects of CD are endothelial dysfunc-
tion [59], platelet abnormalities [60,61] and increased
apoptosis [62]. Thus, it is suggested that intestinal injury,
endothelial dysfunction, platelet abnormalities and
enhanced apoptosis cause increased exposure of phos-
pholipids or new epitopes, which are the origin of aPT,
aPL and aPS/PT autoantibodies. Those antibodies might
play a pathogenic role in the thrombophilia associated
with CD.
New light was recently shed on the ‘inflammation coagu-
lation crosstalks’ [63]. Recent studies have unveiled molecu-
lar underpinnings of the intimate interconnection between
both systems. Being a classical inflammatory state, CD can
present such crosstalks, resulting in enhanced coagulability
in the intestinal arena and on the systemic level. Because
there are several pathways of mucosal injury, autoantigens
like phospholipids, phosphatidylserine and prothrombin are
exposed, inducing the production of aPS/PT, aPL and aPT
antibodies. With their thrombogenic capacities, those auto-
antibodies can present the first or an additional hit in the
thrombogenic background operating in CD. Because of the
increased coagulability in CD and the harmful potential
consequences, patients positive for those antibodies should
be considered to receive preventive anticoagulant therapy.
Conclusions
We detected increased incidence of aPS/PT IgG in the
pediatric celiac group and intermediate incidence in
their parents, compared with no incidence in the control
group. Additionally, higher rates of activity for aPS/PT
IgM and prothrombin IgG autoantibodies were observed
in the patients with CD compared with the other two
groups. Based on the extensive literature of thrombo-
embolic phenomenon described in CD, it seems that the
thrombophilic autoantibodies studied here are operative
in CD, extending the hypercoagulability network of the
disease. The use of the autoantibodies described in this
study as potential markers for thromboembolic manifes-
tations in CD is a subject for future exploration.
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